Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database
Journal of Thrombosis and Thrombolysis · 2025
DOI: 10.1007/s11239-025-03088-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Orly Leiva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. oleiva@bu.edu. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Ischemia, Patient Readmission, Peripheral Arterial Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are at increased risk of atherosclerosis, including peripheral arterial disease (PAD). Critical limb ischemia (CLI) may complicate PAD and is associated with significant mortality and morbidity. Despite the increased risk of thrombosis with MPN, outcomes of CLI in MPN patients are unclear. We conducted an analysis utilizing the 2017-2020 National Readmission Database (NRD) of patients hospitalized for CLI with and without MPN. Patients with MPN were propensity score matched (PSM) with patients without MPN. Primary outcome was composite outcome of major adverse cardiovascular and limb events (MACLE). Logistic regression was utilized to estimate risk of MACLE in patients with MPN vs. without MPN. Inverse-probability treatment weighted (IPTW) analysis was performed to evaluate the effect of revascularization on MACLE in patients with MPN. A total of 102,598 patients were included, 931 (0.9%) had MPN. After PSM, MPN was associated with increased risk of MACLE (47.3% vs. 39.1%; OR 1.40, 95% CI 1.21-1.62). After IPTW, revascularization was associated with decreased risk of MACLE among patients with MPN (45.0% vs. 50.7%; OR 0.80, 95% CI 0.66-0.96). Among patients admitted with CLI, MPN was associated with increased risk of MACLE especially ET and MF phenotypes. Revascularization was associated with decreased risk of MACLE among patients with MPN. Further investigation is needed in order to improve outcomes in patients with MPN and CLI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. oleiva@bu.edu.
- Section of Cardiology- Heart Failure, Department of Medicine, University of Chicago, Chicago, IL, USA. oleiva@bu.edu.
- Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
- Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ghobbs@partners.org.
Zitieren
APA
Leiva, O., Lee, M. H., How, J., Berger, J. S., & Hobbs, G. (2025). Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03088-0
Vancouver
Leiva O, Lee MH, How J, Berger JS, Hobbs G. Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03088-0
BibTeX
@article{Leiva2025,
author = {Leiva, Orly and Lee, Michelle H and How, Joan and Berger, Jeffrey S and Hobbs, Gabriela},
title = {Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2025},
doi = {10.1007/s11239-025-03088-0}
}
EUVIMED